Cyclopropylamines as lsd1 inhibitors
US-2015225375-A1 · Aug 13, 2015 · US
Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas
US10849898B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10849898-B2 |
| Application number | US-201916709874-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 10, 2019 |
| Priority date | Aug 10, 2016 |
| Publication date | Dec 1, 2020 |
| Grant date | Dec 1, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
First claim
Opening claim text (preview).
We claim: 1. A method for the treatment of human merkel cell carcinoma comprising administration to a patient in need thereof an effective amount of a compound having the structure of: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the administration is oral administration. 3. The method of claim 1 , wherein the effective amount of the compound comprises about 1.5 mg/kg to about 10 mg/kg. 4. The method of claim 1 , wherein the compound is combined with at least one pharmaceutically acceptable excipient. 5. The method of claim 1 , wherein the compound is in the form of a tablet, pill, sachet, or capsule of hard or soft gelatin. 6. The method of claim 5 , wherein the compound is in the form of a tablet. 7. The method of claim 5 , wherein the compound is in the form of a pill. 8. The method of claim 5 , wherein the compound is in the form of a sachet. 9. The method of claim 5 , wherein the compound is in the form of a hard gelatin capsule. 10. The method of claim 5 , wherein the compound is in the form of a soft gelatin capsule. 11. The method of claim 1 , wherein the compound is in the form of a capsule comprising the compound at dosage strengths of about 0.50 mg, about 0.75 mg, or about 2.00 mg. 12. The method of claim 11 , wherein the compound is in the form of a capsule comprising the compound at a dosage strength of about 0.50 mg. 13. The method of claim 11 , wherein the compound is in the form of a capsule comprising the compound at a dosage strength of about 0.75 mg. 14. The method of claim 11 , wherein the compound is in the form of a capsule comprising the compound at a dosage strength of about 2.00 mg.
Assignees
Inventors
Classifications
having two nitrogen atoms, e.g. dilazep · CPC title
- A61K31/513Primary
having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title
the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title
for cancer (immunoassay for cancer G01N33/575) · CPC title
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10849898B2 cover?
- Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
- Who is the assignee on this patent?
- Celgene Quanticel Res Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/513. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).